ALT - Altimmune, Inc.
About Altimmune, Inc. (https://altimmune.com)
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Scot Roberts | Chief Scientific Officer | 1959 | $683,229 USD |
| Gregory L. Weaver | Chief Financial Officer | 1956 | $619,694 USD |
| Raymond Jordt | Chief Business Officer | 1973 | $578,850 USD |
| Christophe Arbet-Engels | Chief Medical Officer | 1963 | $361,356 USD |
| Jerome Benedict Durso | Chairman, CEO & President | 1968 | $50,941 USD |
| Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller | 1988 | – |
| Bertrand Georges | Chief Technology Officer | – | – |
| Linda Richardson | Chief Commercial Officer | 1964 | – |
| Robin E. Abrams | Chief Legal Officer & Corporate Secretary | 1964 | – |
| Tony Blandin | Vice President of Quality & Compliance Management | – | – |